Search research articles
Contact Us
Filters
Showing results (891-900 of 903) with videos related to
Page
of 91
Sort By:
Blood Advances
|
October 23, 2023
A study to assess the efficacy of enasidenib and risk-adapted addition of azacitidine in newly diagnosed IDH2-mutant AML
Sheng F Cai, Ying Huang, Jennie R Lance, et al.
Journal of the National Comprehensive Cancer Network : JNCCN
|
September 3, 2016
NCCN Guidelines Insights: Non-Hodgkin's Lymphomas, Version 3.2016
Steven M Horwitz, Andrew D Zelenetz, Leo I Gordon, et al.
Journal of the National Comprehensive Cancer Network : JNCCN
|
March 10, 2017
NCCN Guidelines Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 1.2017
William G Wierda, Andrew D Zelenetz, Leo I Gordon, et al.
Cancer
|
April 20, 2023
Entospletinib with decitabine in acute myeloid leukemia with mutant TP53 or complex karyotype: A phase 2 substudy of the Beat AML Master Trial
Vu H Duong, Amy S Ruppert, Alice S Mims, et al.
Nature Communications
|
January 7, 2023
Dysregulation of PRMT5 in chronic lymphocytic leukemia promotes progression with high risk of Richter's transformation
Zachary A Hing, Janek S Walker, Ethan C Whipp, et al.
Leukemia
|
November 28, 2023
Sex-associated differences in frequencies and prognostic impact of recurrent genetic alterations in adult acute myeloid leukemia (Alliance, AMLCG)
Michael Ozga, Deedra Nicolet, Krzysztof Mrózek, et al.
Blood Advances
|
August 7, 2024
Beat-AML 2024 ELN-refined risk stratification for older adults with newly diagnosed AML given lower-intensity therapy
Fieke W Hoff, William G Blum, Ying Huang, et al.
Cancer Discovery
|
February 2, 2018
BRD4 Profiling Identifies Critical Chronic Lymphocytic Leukemia Oncogenic Circuits and Reveals Sensitivity to PLX51107, a Novel Structurally Distinct BET Inhibitor
Hatice Gulcin Ozer, Dalia El-Gamal, Ben Powell, et al.
American Journal of Hematology
|
July 3, 2026
Signaling Mutations Negate the Favorable Impact of NPM1 Mutations in Older Patients With Newly Diagnosed Acute Myeloid Leukemia Treated With VEN/HMA
Fieke W Hoff, Joshua F Zeidner, Geeta Torlapati, et al.
The Journal of Clinical Investigation
|
September 4, 2013
PP2A-activating drugs selectively eradicate TKI-resistant chronic myeloid leukemic stem cells
Paolo Neviani, Jason G Harb, Joshua J Oaks, et al.
Page
of 91
Search research articles
Search
Showing results (891-900 of 903) with videos related to
Sort By:
Page
of 91
Blood Advances
|
October 23, 2023
A study to assess the efficacy of enasidenib and risk-adapted addition of azacitidine in newly diagnosed IDH2-mutant AML
Sheng F Cai, Ying Huang, Jennie R Lance, et al.
Journal of the National Comprehensive Cancer Network : JNCCN
|
September 3, 2016
NCCN Guidelines Insights: Non-Hodgkin's Lymphomas, Version 3.2016
Steven M Horwitz, Andrew D Zelenetz, Leo I Gordon, et al.
Journal of the National Comprehensive Cancer Network : JNCCN
|
March 10, 2017
NCCN Guidelines Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 1.2017
William G Wierda, Andrew D Zelenetz, Leo I Gordon, et al.
Cancer
|
April 20, 2023
Entospletinib with decitabine in acute myeloid leukemia with mutant TP53 or complex karyotype: A phase 2 substudy of the Beat AML Master Trial
Vu H Duong, Amy S Ruppert, Alice S Mims, et al.
Nature Communications
|
January 7, 2023
Dysregulation of PRMT5 in chronic lymphocytic leukemia promotes progression with high risk of Richter's transformation
Zachary A Hing, Janek S Walker, Ethan C Whipp, et al.
Leukemia
|
November 28, 2023
Sex-associated differences in frequencies and prognostic impact of recurrent genetic alterations in adult acute myeloid leukemia (Alliance, AMLCG)
Michael Ozga, Deedra Nicolet, Krzysztof Mrózek, et al.
Blood Advances
|
August 7, 2024
Beat-AML 2024 ELN-refined risk stratification for older adults with newly diagnosed AML given lower-intensity therapy
Fieke W Hoff, William G Blum, Ying Huang, et al.
Cancer Discovery
|
February 2, 2018
BRD4 Profiling Identifies Critical Chronic Lymphocytic Leukemia Oncogenic Circuits and Reveals Sensitivity to PLX51107, a Novel Structurally Distinct BET Inhibitor
Hatice Gulcin Ozer, Dalia El-Gamal, Ben Powell, et al.
American Journal of Hematology
|
July 3, 2026
Signaling Mutations Negate the Favorable Impact of NPM1 Mutations in Older Patients With Newly Diagnosed Acute Myeloid Leukemia Treated With VEN/HMA
Fieke W Hoff, Joshua F Zeidner, Geeta Torlapati, et al.
The Journal of Clinical Investigation
|
September 4, 2013
PP2A-activating drugs selectively eradicate TKI-resistant chronic myeloid leukemic stem cells
Paolo Neviani, Jason G Harb, Joshua J Oaks, et al.
Page
of 91